WALVAX BIOTECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.33 CNY | +3.54% |
|
+2.43% | -39.05% |
| 26/04 | Walvax Biotechnology's Profit Drops 92%, Operating Income Slids 28% in Q1 2024 | MT |
| 25/04 | Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial | MT |
| Sales 2024 * | 4.13B 570M 47.55B | Sales 2025 * | 5.36B 740M 61.73B | Capitalization | 22.92B 3.16B 264B |
|---|---|---|---|---|---|
| Net income 2024 * | 781M 108M 8.99B | Net income 2025 * | 1.12B 155M 12.9B | EV / Sales 2024 * | 4.54 x |
| Net cash position 2024 * | 4.17B 575M 47.98B | Net cash position 2025 * | 4.77B 658M 54.84B | EV / Sales 2025 * | 3.38 x |
| P/E ratio 2024 * |
29.2
x | P/E ratio 2025 * |
20.6
x | Employees | 2,388 |
| Yield 2024 * |
0.7% | Yield 2025 * |
0.84% | Free-Float | 27.42% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | +3.54% | ||
| 1 week | +2.43% | ||
| Current month | -6.83% | ||
| 1 month | -10.77% | ||
| 3 months | -22.54% | ||
| 6 months | -34.51% | ||
| Current year | -39.05% |
1 week
13.13
14.47
1 month
13.1316.12
Current year
13.1323.66
1 year
13.1332.23
3 years
13.1396.73
5 years
13.1396.73
10 years
5.0596.73
| Managers | Title | Age | Since |
|---|---|---|---|
Run Sheng Jiang
PSD | President | 67 | 22/16/22 |
Hua Zhou
DFI | Director of Finance/CFO | 57 | 23/14/23 |
Shao zhong Dong
BRD | Director/Board Member | 56 | 27/22/27 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ling Bing Zeng
BRD | Director/Board Member | 67 | 13/22/13 |
Zhen Huang
BRD | Director/Board Member | 61 | 01/03/01 |
Yun Chun Li
CHM | Chairman | 62 | 23/09/23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 14.33 | +3.54% | 24,848,250 |
| 25/24/25 | 13.84 | -2.12% | 26,536,100 |
| 24/24/24 | 14.14 | -0.77% | 13,425,930 |
| 23/24/23 | 14.25 | -0.28% | 14,354,610 |
| 22/24/22 | 14.29 | +2.14% | 14,827,800 |
End-of-day quote Shenzhen S.E., April 26, 2024
More quotes
Walvax Biotechnology Co. specialises in the research, development, manufacturing and marketing of human vaccines. Products include vaccines against haemophilus influenzae, meningitis, septicaemia, meningococcal disease, etc.
Sector
Pharmaceuticals
Calendar
26/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
14.33
CNY
Average target price
20
CNY
Spread / Average Target
+39.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -39.05% | 3.16B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- 300142 Stock
